The Biosimilars Forum Applauds Senators Bennet and Cornyn for Re-Introducing Bipartisan Legislation to Incentivize Biosimilars and Lower Cost for Seniors

The Increasing Access to Biosimilars Act Will Support Access to Lower-Cost Biosimilars for Seniors and America’s Healthcare System

Juliana M. Reed, executive director of the Biosimilars Forum, released the following statement after Michael Bennet (D-CO) and Senators John Cornyn (R-TX) reintroduced the Increasing Access to Biosimilars Act. This legislation will enhance physician reimbursement when prescribing biosimilars, realigning incentives to increase utilization of lower-cost biosimilars in Medicare Part B and generate significant health care savings. 

“The Biosimilars Forum and our members applaud Senator Bennett and Senator Cornyn for advancing this bipartisan legislation to incentivize lower-cost biosimilars and address America’s prescription drug affordability crisis, especially for seniors. This is a significant step in the right direction in making biosimilars more readily available and accessible to patients. This legislation will boost competition and encourage physicians to prescribe safe and effective biosimilar medications with lower out-of-pocket costs.

“The Increasing Access to Biosimilars Act will help bring biosimilars to the market more quickly, ensure biosimilars can reach patients, and lower everyday healthcare costs for Americans. The great work of Senator Bennett and Senator Cornyn will address the prescription drug affordability crisis, and biologic medicines are at the center of it. Despite being just 5% of total prescriptions in the U.S., biologics account for the majority of the nation’s drug spending and costs.

“Biosimilars are the commonsense and proven solution to prescription affordability crisis. Together, biosimilars have already saved the U.S. health care system $81.6 billion, including $25.4 billion in 2025 alone. Americans deserve to be able to afford the treatments they need for serious conditions such as cancer, autoimmune diseases, diabetes, and more. We are excited to see members of Congress prioritize American patients who want access to affordable, safe, and effective medicines.

“Biosimilars generate billions in cost-savings for the Medicare program as prices continue to increase for reference biologic drugs. Biologic drugs—some of the most expensive drugs available—are estimated to cost Medicare Part B and its enrollees upwards of $32 billion annually. Making biosimilars more available to the Medicare program has the potential to save billions of dollars each year. 

“Nearly 30% of Americans say they have not taken their medication as prescribed due to unaffordable prices. FDA-approved biosimilars are on average more than 50% lower-cost than the originator biologics they reference. Biosimilars are a key component of the solution to fix America’s healthcare affordability crisis. 

“Today, 100 biosimilars have been approved by the FDA in the United States across dozens of disease states. The potential of biosimilars is enormous. In fact, the next five years could see an increase in savings up to $181 billion for Americans and the healthcare system. 

“Ensuring biosimilars reach the patients is especially important considering the ‘biosimilar void.’ Of the 118 biologics expected to lose patent protection over the next decade, only 10 percent currently have biosimilars in development. This void in the biosimilar market significantly limits potential savings to the healthcare system, and steps to streamline development and approval can help mitigate its detrimental impact on the industry.

For more information on the Biosimilars Forum’s work to increase access to lower-cost biosimilars, visit biosimilarsforum.org.

+++

MEDIA CONTACT:

Scott Lusk

Signal Group, Managing Director

202-288-3233; slusk@signaldc.com